The Biden administration said on Monday that it plans to end the nationwide COVID-19 public health emergency on May 11. When the PHE ends, COVID-related 340B program flexibilities announced in March 2020 could end too.
The U.S. Health Resources and
…
The American Hospital Association yesterday asked to meet with the team of federal officials that will decide how the government will repay 340B hospitals for five years’ worth of illegal Medicare Part B drug reimbursement cuts. The amount of refunds
…
Drug manufacturer Astellas will let 340B covered entities using “a compliant 340B inventory replenishment model” count accumulations of its antifungal Cresemba under its old National Drug Code toward replenishment of equal quantities under the product’s corresponding new NDC, the company
…
The Pennsylvania Department of Human Services yesterday rescinded Medicaid policy guidance dated Dec. 22 and effective Jan. 1 that forbade 340B covered entities’ contract pharmacies from dispensing 340B-purchased drugs to Medicaid beneficiaries.
The state primary care association warned that the
…
Annual recertification of 340B eligibility for federally qualified health centers and most other grantee-type entities will start Jan. 30 and end Feb. 27, the U.S. Health Resources and Services Administration said yesterday.
HRSA did not say when Title X family
…
Pennsylvania 340B health centers and hospitals are alarmed about a Dec. 22 state human services department notice to providers that 340B covered entities’ contract pharmacies “must dispense non-340B-purchased drugs to [Medicaid] beneficiaries in the [fee for service] and managed care
…
The U.S. Centers for Medicare & Medicaid Services will publish the first 10 Medicare Part D drugs selected for the new Medicare Drug Price Negotiation Program by Sept. 1, CMS announced yesterday.
The negotiated maximum fair prices for these drugs
…
Federal Medicare officials plan to issue a proposed rule in April regarding “potential remedies” for illegal Part B drug payment cuts for 340B hospitals from 2018 through late September 2022.
The Centers for Medicare & Medicaid Services revealed April as
…
Swiss eye care drug manufacturer Alcon is providing refunds for charges above 340B ceiling prices on 22 NDCs for varying sales periods from Q3 2019 through Q3 2022.
The U.S. Health Resources and Services Administration posted Alcon’s public notice about
…*Sign up for news summaries and alerts from 340B Report